Scaling Tech into Successful Companies
STALICLA SA, a near clinical stage Swiss Biotech company leading the field of precision medicine for Neurodevelopmental Disorders (NDDs) - including conditions like Autism Spectrum Disorder (ASD) or Developmental Delay - today announced the successful closure of the second tranche of its series A for an amount of USD 8M (CHF 7.7M).
Lynn Durham, fondatrice de la startup genevoise Stalicla, veut proposer un traitement personnalisé adapté à chaque patient.
CEO & Founder, Lynn-Allison Durham will be speaking on expert panel on NeuroTech, software and diagnostics- at hashtagSACHS_NIF _Pre-JP Morgan in San Francisco. She will share STALICLA’s experience of developing a highly domain specific AI platform to accelerate precision medicine for patients with neurodevelopmental disorders